Alto Neuroscience reports favorable ALTO-300 Phase 2b interim analysis; final data expected mid-2026

Alto Neuroscience, Inc.

Planned interim analysis recommended continuing study with ~200 biomarker-positive patients in final sample.
Topline results from the Phase 2b trial of ALTO-300 are expected in mid-2026.
Company reported preliminary 2024 year-end cash of ~$168M, expected to fund operations into 2028.
Interim analysis included 87 biomarker-positive patients after in-depth site and patient eligibility review.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.